BSG Guidelines: Suspected Liver Disease

November 20, 2026 • 00:37:12
BSG Guidelines: Suspected Liver Disease
BSG From Top to Bottom
BSG Guidelines: Suspected Liver Disease

Nov 20 2026 | 00:37:12

/

Show Notes

Professor Stuart McPherson, Chair of the BSG Guideline Development committee, is joined by co-authors Professor Ashwin Dhanda and Dr Wen Hao Lee to discuss the updated BSG guidelines on the investigation of suspected liver disease, published in Gut.

Replacing the 2018 guidance on abnormal liver function tests, the guidelines now cover anyone with suspected liver disease and are aimed at primary care and specialist clinicians alike. The panel explains the liver blood panel, reflex AST testing, the recommended aetiology screen, and the two-step fibrosis pathway (FIB-4 followed by ELF or transient elastography), along with referral red flags, community management and three-yearly reassessment. They also cover new recommendations on case finding in high-risk groups, including a new audit standard for people with diabetes. 

For more information and to view the guidelines clcik here: https://www.bsg.org.uk/clinical-resource/bsg-guidelines-on-suspected-liver-disease

Chapters

View Full Transcript

Episode Transcript

[00:00:00] Speaker A: Foreign. Welcome, everyone. Thank you very much for listening to our podcast about the recently updated BSG guidelines on the investigation of suspected liver disease that have been published in Gut. I am Professor Stuart McPherson, a hepatologist from Newcastle and also vice President of the BSG and I was chair of the Guidelines Line Development Group. It's a great pleasure to have Ashwin Danda and Wenhou Lee with me, who were two co authors on the guidance. So Ashwin and Wenhou are going to introduce themselves. [00:00:45] Speaker B: Yep. Hello, everyone. It's Ashwin down here. So, I'm a Professor of Liver Medicine at the University of Plymouth and I'm also a member of the liver section of the bsg and I helped develop this guideline by leading one of the subgroups that was mainly addressing liver etiology panels and imaging. [00:01:07] Speaker C: Afternoon, everybody. I'm Wen Hao Lee. I'm a clinical lecturer based in London. I'm a hepatology registrar and the national trainee representative for Basel. My involvement in this project was in the fibrosis assessment section of the guideline and also I'm chiefly responsible for all the figures in the new guidelines. [00:01:30] Speaker A: Thanks to both of you and Wenhou, yep, your figures are great in the guidelines, so everyone will really enjoy them and we know that's a lot of work to get them right. And thanks to both of you for your contributions to that. Let's just get on. We're going to have a bit of a discussion about the guidelines. So, Ashwin, why are these guidelines needed and what do they really address? [00:01:52] Speaker B: They are a big revision on our last set of guidelines, which are from 2018, and those ones were actually labeled abnormal liver function tests. So the focus has changed from just dealing with how we manage abnormal blood tests to more about how do we assess potentially significant liver disease in different populations. So we're moving to be more general to apply to everyone and not just people who've had a liver blood test. And we have included a lot more detail about management of the early assessment of the etiology, as well as screening in different populations and how we would go ahead and manage those different cases and different populations. [00:02:40] Speaker A: And so, yeah, I mean, the guidelines are investigating all those things. Why else do we need these guidelines, do you think? There's clearly a lot of liver disease out in the community, but who's going to be using these guidelines, do you think? [00:02:57] Speaker B: Well, there's several reasons why we need new guidelines. First of all, there's a rising prevalence and incidence of liver disease in the uk, so we're all going to see a lot more of it. Secondly, a lot of it is managed by primary care in the community. So these guidelines are there for everyone, not just for specialists who manage just liver disease, but they're targeted at primary care practitioners as, as well as general physicians, people who practice gastroenterology in general, as well as hepatologists. [00:03:33] Speaker A: Yeah. So I'll move over to how now. So Ashwin's alluded to the fact that there's been an expansion beyond the investigation of raised liver blood tests. Just. Could you talk about how the main routes are to people being suspected with liver disease in the first place and how the guidelines might address that? [00:03:52] Speaker C: Sure. So, in terms of the new guidelines, what we've really focused on is essentially for the people who are suspected to have liver disease, we have separated those based on whether they have any symptoms associated with liver disease, whether they have any radiological evidence, suggest a potential liver disease, particularly either cirrhosis or they've got excess fat or steatosis on their imaging. And also having this new guidelines catered for everybody, there are, of course, sort of. We know based on all the studies we've done over the, over the last couple of decades that there are specific populations that are particularly prone to having liver disease. So having a specific section on focusing on those particularly with alcohol excess and also who have type 2 diabetes and obesity. So those are the. What we call in our. In the guidelines as especially sort of at risk populations. So those are the main areas and sections that we focused on in our new guidelines in terms of investigation for people with suspected liver disease. So symptoms, abnormal blood tests, imaging and also case finding. They're the four main sections that we have focused on in this guideline. [00:05:16] Speaker A: Yeah. So it might be helpful for us just to break up the question into those areas. So clearly the previous guidelines were very much focused on liver blood tests, so we'll start with that before we move on to the other areas. So back to Ashwin. So could you just tell us about what a standard liver blood test panel includes and what those tests are measuring and might signify? [00:05:40] Speaker B: Yeah, absolutely. So this isn't really changed from our 2018 guidance. So the standard panel still includes ALT, so Amino Alanine aminotransferase, as well as albumin, bilirubin and alkaline phosphatase, as well as gamma gt. So those give a broad panel that measure different aspects of liver function. So the ALT measures hepatocyte function and hepatocyte death. When it goes up, the alkaline phosphatase and gamma GT measure biliary damage. And so they are more of a measure to identify cholestatic or biliary disease. And then bilirubin and albumin will pick up more advanced forms of disease, chronic liver disease or cirrhosis. So that combination has been shown to pick up asymptomatic liver disease in large cohort studies, with the addition of the gamma GT being more useful to pick up cases who have steatotic liver disease as well. [00:06:52] Speaker A: Okay, great. I guess we should emphasize that people can still have significant liver disease with normal liver blood tests, but we must be investigating patients who have raised liver enzymes. And what about ast? Why is AST not in the standard panel? [00:07:09] Speaker B: Yeah, good question. AST is another measure of hepatocyte function and it is a great marker of liver damage, but it isn't specific. So other cell types produce ast, such as cardiac muscle. And also the main limiting factor is that it is not widely available as a routine analyte in most laboratories. So the additional benefit is when you add it in to the alt, so you can see the difference between the ALT and astronomy. [00:07:45] Speaker A: Okay, great. And could you just tell us a bit more about the different patterns of abnormality and what people should look for in the liver enzymes and maybe what some of the causes are for those abnormal patterns? [00:07:59] Speaker B: Yeah, sure. So where there's hepatitis, predominant patterns, so liver injury causing hepatocyte death or damage will cause an increase in the ALT and AST predominantly. So causes of those are often viruses. So viral hepatitis B and C, but also in the acute phase, hepatitis A, hepatitis E, epsilon Barr virus, cytomegalovirus, and often those elevations can be significant, sometimes as much as more than 1,000. Other causes that might cause a high ALT are things like a drug induced liver injury as well as autoimmune hepatitis. Those are the predominant ones. And then thinking about cholestatic pattern of liver abnormalities that tends to be with a high alkaline phosphatase and gamma GT if there's also biliary obstruction or a late form of damage with cholestatic liver injury, then bilirubin might also go up, causing jaundice. And the causes of those might be related to biliary obstruction. So whether that is gallstones or malignancy, but also immune diseases such as primary biliary cholangitis and primary sclerosing cholangitis. So I think I've covered most of them. I don't know whether how you want to add anything else in there that I might have missed. [00:09:33] Speaker C: I think you covered it pretty comprehensively. I think the only other one I can think of would be sort of sometimes you can get isolated raised bilirubin. So rarer causes should always think about sort of Gilbert's or Gilbert syndrome and also hemolysis as a potential differential. And yeah, I think other than that, if you thinking that if the ASD is significantly higher than the alt, that increases your suspicion of perhaps alcohol related hepatitis. And again, if it's sort of isolated ALP rises, think about the non liver related causes like Paget bone metastasis, or if it's a female of childbearing age thinking about pregnancy and such like. But apart from that, I think you covered it pretty comprehensively. [00:10:24] Speaker A: Yeah, I think you have. And in the guideline there's a nice big table that shows potential causes and patterns in more detail. So when you get to read the guidelines, do refer to that. As we've alluded to, the AST is not recommended in the the panel, but the guidelines are very much talking about reflex AST measurement. Just talk to us about what is reflex testing and what is the significance of all of this for patients. [00:10:58] Speaker C: So I think reflex testing means systems in place where essentially this is done on an automatic basis. And a great example of this over the last couple of years that has seen significant success and implementation is the Intelligent Liver Function Test coming out of Scotland. These systems, like the Intelligent Liver Function Test, essentially automates liver function testing. In the absence of having a clinician or healthcare professional click on specific tests, they are done based on any abnormal blood results as the first layer of test and they automatically triggers a liver screen blood test and AST is part of that. And through this whole process, the rationale for this is to try and increase the amount of early detection of liver disease, particularly in the primary care setting. And also in the context of an ast, as we've already alluded to, one of the disadvantages of not having an AST is that it is a core component of a FIB4 test, which we use to try as a first line test to detect those with suspected advanced liver fibrosis. So having a reflex testing where you can incorporate an AST as part of that is that you're then able to then perform a fib 4 which can then feed into pathways of community pathways and hospital pathways for identifying those with suspected or potentially significant liver fibrosis, which can. Those patients can then be then referred onto appropriate secondary care settings for further assessment of their liver disease. [00:12:53] Speaker A: Yeah, I mean, this is really important. We know that raised liver blood tests are frequently not followed up. So reflex systems that ensure that appropriate etiological testing and fibrosis testing are undertaken to stage people and get a diagnosis is absolutely vital. And, and the only way we're going to reduce that variability is through reflex testing. So the guideline is very much encouraging that, because we know that these tests can be reflex tested and are done in many places. So hopefully that will have an impact in due course. In terms of etiology, we know that when someone has raised liver blood tests, the question should always be what is the cause of that and what is the stage of fibrosis? So what tests should we be doing in the standard etiology clinic or particularly primary care physicians, should they be doing before they refer the patient? Ashwin, do you want to answer that one? [00:13:51] Speaker B: Yeah, sure. So I think it's not just about doing the biochemical and blood tests, but also it needs to include a comprehensive clinical history and examination, particularly thinking about risk factors for liver disease. So alcohol use, metabolic risk factors, blood pressure, body mass index to think about risk, metabolic risk factors for MASLD and potentially toxic medications as well. And then the liver screen itself, in terms of the blood tests needs to include a variety of viral serology markers. So hepatitis, biological B surface antigen, hepatitis C antibody and those, as we mentioned before, need to have follow up reflex testing if either of them are positive so that we can have more information. So the hepatitis C antibody needs to be followed up with reflex RNA testing and the hepatitis B needs to include further serology testing and hepatitis delta testing. So moving on from the viral hepatitis serology, we would also recommend an autoimmune liver profile, which should include an antimitochondrial antibody, an anti smooth muscle antibody and antinuclear antibody, as well as serum immunoglobulins. And then screening for hemochromatosis, we should include a serum ferritin and transferrin saturation. And then finally the metabolic risks need to be looked at with the HbA1c and lipid profile. So I think those are slightly expanded compared to our previous recommendation. And I think the importance is also to think about the potential relevant risk factors for each individual that's in front of you. [00:15:43] Speaker A: Yeah, completely agreed. And then what about patients who may have more significantly raised liver blood tests? So alt greater than 10 times the upper limit of normal. How does the screen for a patient presenting like that differ from the standard screen? [00:16:01] Speaker B: Yeah, so I think if that's the case, where there's a very High level of ALT or ast, then we've got to think about a viral cause or a drug induced liver injury, for example, or immune condition. So we would, as well as doing the regular viral serology, we need to expand that to include hepatitis A and E as well as EBV and CMV and include the autoimmune profile and immunoglobulins. So, yeah, I think that's the key difference, really. [00:16:29] Speaker A: Yeah, agreed. And then there may be more specialist tests that secondary care will conduct in addition to those things. Ultrasound is obviously the first line imaging modality for people with liver disease. But when might it be appropriate to use CT or mrcp? [00:16:48] Speaker C: So I think CT and MRCPA are obviously predominantly sort of hospital based or secondary care investigations. So CT for suspected hepatopancreative biliary, particularly if you think about potential cancers, will be very, very helpful. And in the context of mrcp, the chief indication would be those of suspected biliary disorders. So in the context of gastroenterology and hepatology, particularly think about those people with underlying inflammatory bowel disease coupled with abnormal liver function test to be potentially screening for psc, which is important. So, yeah, chiefly I would say cancer and biliary disease are the main two reasons for considering CT and mrcpo vultures. And [00:17:44] Speaker B: there is one other condition in which we should think of an MRC specifically, and that's in people who've got a history of inflammatory bowel disease with abnormal liver function tests, who we're thinking potentially have primary sclerosing cholangitis. So potentially in that group we go straight for an mrcp. [00:18:03] Speaker A: Yeah, absolutely, agreed. And yeah, the other modalities are just not centered enough to pick it up. So these days patients get imaging for all sorts of reasons and liver disease is very commonly picked up. So watch. How should one approach a patient who has suspected steatosis on an imaging modality? [00:18:25] Speaker C: I think this is a very common problem, particularly in primary care, and we certainly see this a lot also in secondary care. I think the most important thing is to take a detailed history to look for the risk factors for steatosis. So obesity, type 2 diabetes, also alcohol excess are the potential key reasons or common reasons for this. And once this has been identified, the next key question is to establish whether this patient is at risk of significant liver fibrosis. So then I would go on to do a non invasive fibrosis testing with a Fib 4 and consider referral to secondary care if they have any evidence of indeterminate or high risk of liver fibrosis. So those that would be fib 4 or more than 1.3 if they are under 65 or greater than 2 if they are more than 65 years old. [00:19:21] Speaker A: All right, and how might things differ if you find someone with suspected liver disease as such, which is obviously different, that something is a bit more solid. There may be a nodular looking liver or evidence of splenomegaly to suggest portal hypertension. How would you approach that? [00:19:39] Speaker C: So I think if you're suspecting someone with underlying liver disease, I think most important thing, as I just said, it would be to assess the level of fibrosis and I think if those thresholds. So the first baseline test we would normally advocate FOR is a Fib4, followed by a second tier liver fibrosis test, either an ELF score or a Fibroscan or VCTE. And we provide details on the exact thresholds for positive ELF and VCT in the guidelines. And then those with positive scores should be then referred to secondary care for further assessment. Assessment. [00:20:25] Speaker A: And should we be doing an etiology screen in these patients as well? [00:20:30] Speaker C: Yes. So in terms of etiology screen, I think we should be screening for alcohol history, screening for cardiometabolic risk factors. And also there are certain medications that are associated with liver fibrosis. We should be thinking about doing blood tests, as Ashwin said previously, in the context of a liver screen. So viral hepatitis, Hep B surface antigens, Hep C antibody and RNA levels, autoantibodies, immunoglobulins, ferritin and transferring saturations for suspected hemochromatosis and HbA1c and lipoprofiles for metabolic risk factors. And then in secondary care, there are obviously extended screens that are perhaps not available or suitable for primary care, that, that those are suspected for rarer Things such as Alpha 1 Antitrypsin or Celiac Screen or Wilson's and also sexual sexually transmitted infection screens. So these are some of the extended screens that we would perhaps consider in secondary care settings, along with some imaging, primarily a liver ultrasound to begin with. [00:21:41] Speaker A: All right, so to guess summarizing that someone with suspected steatosis, we do assess the the risk factors for steatosis and stage the fibrosis if it's suspected liver disease, I.e. nodular looking liver or portal hypertension. We need etiology screen, fibrosis assessment as well. Brilliant. [00:22:04] Speaker B: Yeah. So I think, Stuart, you've asked enough of the questions now, so I think it's your turn to be put on the spot. So should we move over to FIBROSIS staging, and we briefly touched upon this just now. So the guidelines talk about a two step sequential testing pathway for fibrosis, starting with Fib4. So can you tell us a little bit more about each of the steps in that pathway, Stuart? [00:22:31] Speaker A: Yeah. So essentially every patient with suspected liver disease should have a fibrosis assessment. And there are multiple non invasive tests that are available out there. But probably the most validated first line test that can be conducted virtually Anywhere is the FIB4 score, which is a simple algorithmic test that involves age, AST, ALT and platelet count. And a Fib 4 score that is low below the threshold of 1.3 reliably excludes advanced liver fibrosis or cirrhosis. And that's been widely validated across a number of different diseases. However, if someone has a raised fib above the threshold, there is quite a significant false positive rate associated with that. So those people need to then go on and have a second line test undertaken. And the guidelines suggest that the most commonly used tests are the ELF test, which is a blood test that I'll come back to, or transient elastography, which is an ultrasound based technique. And both those tests are quite widely available across the UK and are accurate at staging fibrosis, and those should be conducted in primary care prior to referral. Now, the ELF test is a blood test that measures markers of collagen metabolism and a score above 9.8 is suggestive of advanced fibrosis. For transient elastography, which is often conducted by Fibroscan, although that's not the only technology out there, a liver stiff measurement above 10 kPa is suggestive of advanced fibrosis or cirrhosis, or the new term compensated advanced chronic liver disease. So the guidelines very much recommend conducting those tests prior to referral because they're widely available. [00:24:36] Speaker B: Yeah. Great. And can you just tell us a little bit more about if there are any particular populations we should be adjusting for the FIB4 score? And what about the disease etiology? Does that matter? [00:24:48] Speaker A: Yes. So, I mean, that's a good question. For simplicity, we have used the same thresholds across disease etiologies, although it's well accepted that the false positive rate for FIB score with alcohol related diseases is. Is high, even higher than it is for metabolic dysfunction associated steatotic liver disease. So we will get more false positives in that scenario. And there may be situations, such as people who are working in addiction services, where people are drinking huge amounts of alcohol, where it's appropriate to go direct to transient elastography and skipping the fib 4 test in that scenario, and that is reflected in our guidance. [00:25:29] Speaker B: Great, thank you. And what about the potential red flags when we shouldn't even bother doing a fibrosis score and just refer directly to secondary care? [00:25:41] Speaker A: So, referring to secondary care, if someone is jaundiced and it's unexplained, they need urgent referral because serious causes such as cancer there or stones blocking the bile duct, etc. Or have hepatic failure. So jaundiced people should be referred urgently to secondary care. And if you're suspecting hepatobiliary malignancy, for example, order the CT scan at the same time as sending an urgent referral to try and speed things along a bit. There are, of course, other situations for an urgent referral. You may still do tests before patients who have have got significantly raised liver blood tests above five times the upper limit of normal. That is unexplained. So you've conducted some investigations, those have persisted. The liver screen may be negative and you're not sure what's going on, so those can be referred in urgently. Other scenarios that do require referrals obviously suspected advanced fibrosis cirrhosis. So if the fibrosis tests, as I've suggested, if there is imaging evidence of cirrhosis or portal hypertension, they should be referred in. I guess the urgency there would be dependent on. On what the blood tests are showing. If there's evidence of synthetic dysfunction from the liver, then that will be urgent, whereas it may be routine if the blood tests are otherwise stable, don't know how. Any other thoughts on people who should be referred in? [00:27:13] Speaker C: No, I think that's. You've covered it really well there. Sure. I think the only additional thing I would say is just going back to the Fib 4 thresholds that we've kind of added on in terms of age. It's important because I get a lot of questions from sort of particularly primary care colleagues about what thresholds they should be referring patients to. And obviously in our guidelines, we specifically said the. For those who are older than 65, they have a slightly higher threshold for Fib4 in terms of cutoffs for referral. But I think it's also important to say that fib4 has been shown. In fact, your work from over 10 years ago, I think, showed that in young people, fib4 is also less accurate at predicting advanced fibrosis. So that's also, I think, a limitation that for the field, that's really important given the rising obesity rates. Among young adults, I think that's a, that's a unmet need that the field doesn't really have any true answers for at the moment. So not really sure how. What the best do you would. What's your advice for sort of primary care physicians who sees like a 30 year old. Do you have a specific threshold that would you say still stick to the 1.3 for the fifth for. [00:28:31] Speaker A: That's a very good question, slightly beyond what we've said in the guidance. I think for young people the probability of having advanced fibrosis or cirrhosis is low because you need time to develop that. So that's one of the reasons why the test performs poorly. So I would use the same thresholds at this stage in absence of other evidence. But it. The key thing in this is if people are concerned about advanced fibrosis, even if the tests are negative, then you could still consider doing a different kind of test or referring because we know that these tests are not 100% perfect. And there will be scenarios where you think this person or one thinks this person has more advanced disease than the tests are saying. So if in doubt, the patients can be referred to or seek advice and guidance via advice and guidance. And that is stated in the recommendations? [00:29:30] Speaker B: Yeah. Okay, so we've talked a little bit about which patients need to be referred to secondary care. Can you tell us how about any potential groups of patients that are safely, potentially managed just in primary care? [00:29:45] Speaker C: Sure. I think from the guidelines we think that if you have asymptomatic patients with mildly raised lived with a negative live etiology screen and in the absence of any high fibrosis risk scores and also normal imaging and also you haven't been able to identify any obvious causes for the liver abnormality through your history taking so mainly looking at medications or lifestyle etiologies then in those sort of situations, referral to secondary care is unlikely to change the management of these patients. So these are the people that we wouldn't recommend routinely referring to secondary care in our guidelines. [00:30:32] Speaker B: Yeah. Great. Okay, thank you. Let's just move on a little bit to thinking about managing those patients in the community. So in those people who have had a fibrosis assessment and they don't meet the thresholds for follow up, so they're going to be managed in primary care. What should we do with those patients, how should we manage them and when do we need to repeat their fibrosis assessments? [00:30:58] Speaker A: Yeah, so I mean clearly the etiology is important. So if someone has drinks harmful levels of alcohol, they need to be counseled about that and given appropriate support to address that. Likewise, if they have suspected MASLD as the cause, they need proper advice on diet and exercise, modification of their cardiovascular risk factors, optimisation of their diabetes, etc. So they need managed is one thing, and then they also need a plan for restaging them. And international guidelines vary on this. We have gone for three years based on the fact that the natural history of steatotic liver diseases tends, which is the major disease out in the community, which tends to have quite a slow rate of progression in the majority of people. So if people still have ongoing risk factors after three years, they should have a repeat fibrosis assessment through the pathway. So that is what's recommended. I mean, this gets more challenging now that we have people who are placed on GLP1 analogues and suddenly have lost 20kg in weight and that completely changes the situation. So hopefully we'll have patients who then don't need fibrosis assessment in the future because they've completely turned off the disease process. But yeah, that's work in progress in terms of that, but must think about a three yearly reassessment. [00:32:26] Speaker C: Moving on to the screening and case finding sections of the new guidelines, maybe I can ask you, Ashwin, the guideline recommends against routine and population wide screening for asymptomatic adults. Why do you think broad screening will be counterproductive? [00:32:44] Speaker B: Well, I mean, we know that there is a growing number of patients who have liver disease, mainly driven by alcohol use and steatotic liver disease. But the large cohort studies that have been done looking at universal screening of the whole population, as well as modeling studies, have actually shown that the rates of pickup are very low, less than 1% of people who have advanced chronic liver disease. And because of that, the overall cost effectiveness of such an approach isn't there. So at the moment we don't have enough evidence to push the mandate for universal screening. Instead what we recommend is screening for people at risk, sort of high risk populations for liver disease. And that can involve specific case finding in those populations. So we mentioned some of these earlier on. We can case find for people who have harmful alcohol use, for those who have risk factors for metabolic liver disease with diabetes and obesity, and those who have high risk for viral hepatitis would be the key populations that we can actually target screening at. So potentially for alcohol, that screening could be targeted at alcohol, community alcohol services or through GP practices where they have coding data available for alcohol use. And the same with metabolic liver disease, we could look at patients through primary care coding and invite them for screening with blood tests and doing a two step fibrosis assessment pathway, as we discussed already. And viral hepatitis is already quite widely screened for. But again that's something that can be offered so that there would be a database of people who have got chronic viral hepatitis that may not have had a fibrosis assessment that can be screened as well. Don't know if there's anything else, Stuart, that you wanted to add there? [00:34:50] Speaker A: No, but this is the new part in the guidance that wasn't addressed in the previous one and it is becoming more and more important because liver disease goes undetected and there are. We have also introduced some audit standards within the guidance as well and one of those is around case finding for people with diabetes because we know that between 6 and 15% of people with diabetes, depending whether it's a primary or secondary care cohort, have advanced fibrosis. So we make a recommendation that they should have case finding with fibrosis assessment up until the age of 75, assuming that they have a good performance status and will benefit from a potential diagnosis. So that is a new recommendation and there is an audit threshold of greater than 70% for primary care to try and achieve that. That will be clear work in progress. What we don't yet know is whether case finding in other people with obesity and associated metabolic risk factors, whether that is effective and cost effective. And there is work ongoing in the UK at the moment to try and gather evidence for that. But there is a disconnect between different international guidelines on on who to to go case finding for. But it's a very much a moving field given that there are new therapies for MASLD that hopefully will be approved very soon for use in the UK and are being already being used elsewhere worldwide. So that completely changes the the case finding or the case for case finding if you like. So that's has come to the end of our podcast today. Thank you very much for listening. I hope you've enjoyed it. You can access the guidelines through the GUT website and they are open access where you can get the. The full details and some good figures and, and good summaries of everything. So do access that. A big thanks to Wenhow and Ashwin for their very thoughtful insights into the guidance today and thanks again for listening.

Other Episodes

Episode

November 21, 2025 • 00:15:28
Episode Cover

BSG IBD Guideline - Acute Severe Ulcerative Colitis (ASUC)

Part three of seven: Trainee Gastroenterologist, Jennifer Tham, interviews, Dr. Bel Kok, Consultant Gastroenterologist at the Royal London Hospital and Honorary Senior Lecturer at...

Listen

Episode

September 08, 2026 • 00:15:03
Episode Cover

Gut Microbiome in Acute Pancreatitis

Professor Vikram Mitra (Chair, Pancreas Clinical Section, British Society of Gastroenterology) speaks with Professor Pramod Garg, President of the Indian Society of Gastroenterology, about...

Listen

Episode

August 08, 2025 • 00:25:23
Episode Cover

BSG Sedation Guidelines in Gastrointestinal Endoscopy

Prof. Reena Sidhu, Consultant Gastroenterologist and Honorary Professor at the University of Sheffield, joins Dr. Jabed Ahmed, Gastroenterology Clinical Research Fellow at Imperial College...

Listen